Alzheon was last valued at $1.3B. The company is private, so there is no listed share price.
One company valuation: $1.3B.
Lead investors for each round are in the funding timeline.
The closest biopharmaceutical peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Alzheon is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
